Sun edges closer to docetaxel NDA launch in the US
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries has received US FDA approval for its New Drug Application for Docefrez (docetaxel) injection 20 mg/vial and 80 mg/vial, taking it closer to a potential launch of the product in the US.